NCT03665285View on ClinicalTrials.gov

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

April 11, 2023

Study Completion Date

April 11, 2023

Conditions
Advanced or Metastatic Solid TumorsLung CancerBreast CancerHead and Neck Squamous Cell CarcinomaEndometrial CancerMelanomaCRCUrothelial CarcinomaCholangiocarcinoma
Interventions
DRUG

NC318

NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Trial Locations (6)

10016

Laura and Isaac Perlmutter Cancer Center, New York

17325

Pennsylvania Cancer Specialists and Research Institute, Gettysburg

78240

NEXT Oncology, San Antonio

90025

The Angeles Clinic and Research Institute, Los Angeles

06510

Yale University Cancer Center, New Haven

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

NextCure, Inc.
All Listed Sponsors
lead

NextCure, Inc.

INDUSTRY

NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter